Hematologic Cancers

Bone Imaging With Improved Modalities in Multiple Myeloma

Bone Imaging With Improved Modalities in Multiple Myeloma

By

Bone imaging is a critical aspect of care for patients with multiple myeloma, and recent advances in imaging modalities have improved detection of lytic lesions and bone marrow involvement—but incorporating these new modalities into clinical practice has been challenging.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

By

For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

By

Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

By

Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

By

Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator's choice chemotherapy of CHOP, CVP, or bendamustine.

Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia

Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia

By

Researchers randomly assigned previously untreated patients with CD20-positive CLL to receive obinutuzumab plus chlorambucil, rituximab plus chlorambucil, or chlorambucil alone.

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

By

The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

By

Moffitt Cancer Center investigators believe allo-HCT may actually be "curative" for patients with a certain type of lymphoma.

Rituximab in Frontline Therapy May Reduce the Risk of Transformation in Follicular Lymphoma

Rituximab in Frontline Therapy May Reduce the Risk of Transformation in Follicular Lymphoma

By

The introduction of rituximab has greatly improved outcomes among patients with follicular lymphoma, but its impact on the risk of transformation and post-transformation are unclear.

Value, Not Cost, Should Be Considered for Myeloma Treatment

Value, Not Cost, Should Be Considered for Myeloma Treatment

By

Even though cancer drugs only account for approximately 1% of the total health care spend, physicians can serve as advocates for patients struggling to afford recommended treatments.

For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More

For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More

By

Repeat primary care consultations before a diagnosis was assigned and non-specific symptoms were two factors that caused delays in the diagnosis of patients with myeloma following the appearance of symptoms.

Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Diffuse Large B-Cell Lymphoma

Access detailed treatment regimens for diffuse large B-cell lymphoma, such as R-CHOP with RT and radiotherapy.

Ibrutinib May Be Effective as First-Line Agent in Treatment of Waldenström's Macroglobulinemia

Ibrutinib May Be Effective as First-Line Agent in Treatment of Waldenström's Macroglobulinemia

By

The effectiveness of ibrutinib in the frontline setting has not been definitively established.

Isolated mild/moderate thrombocytopenia may not require intervention

In pediatric patients, low platelet counts are a frequent finding, with underlying causes ranging from completely benign to serious conditions, such as leukemia.

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

By

Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.

Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia

Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia

By

The efficacy of rituximab plus prednisolone had not been evaluated prior to the current study.

Global Burden of Myeloma Increasing, Access to Treatments Lacking

Global Burden of Myeloma Increasing, Access to Treatments Lacking

By

A new study reveals that an aging world population is the predominant contributor to a 126% increase in age-standardized incidence rates of multiple myeloma from 1990 to 2016.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

By

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

By

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

By

In the phase 3 ARROW study patients with relapsed/refractory multiple myeloma were randomly assigned to receive carfilzomib 27 mg/m2 twice-weekly or 70 mg/m2 once-weekly

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

By

CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.

Subcutaneous Daratumumab Plus CyBorD in Newly-Diagnosed Amyloid Light Chain Amyloidosis

Subcutaneous Daratumumab Plus CyBorD in Newly-Diagnosed Amyloid Light Chain Amyloidosis

Raymond L. Comenzo, MD, discusses his findings at the ASCO 2018 meeting.

Long-Term Follow-Up Results of ZUMA-1 Trial

Long-Term Follow-Up Results of ZUMA-1 Trial

Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.

Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma Treatment Regimens

View treatment regimens for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, including combination therapies with bortezomib and more.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs